Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.45 USD | +0.73% | +0.13% | +8.40% |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.95B | Capitalization | 13.6B |
---|---|---|---|---|---|
Net income 2024 * | 1.06B | Net income 2025 * | 1.22B | EV / Sales 2024 * | 7.27 x |
Net Debt 2024 * | 5.75B | Net Debt 2025 * | 5.92B | EV / Sales 2025 * | 6.62 x |
P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
11.1
x | Employees | - |
Yield 2024 * |
2.84% | Yield 2025 * |
3.12% | Free-Float | 95.04% |
Latest transcript on Royalty Pharma plc
1 day | +0.73% | ||
1 week | +0.13% | ||
Current month | +0.36% | ||
1 month | -2.72% | ||
3 months | +8.71% | ||
6 months | +14.04% | ||
Current year | +8.40% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 227 M€ | +6.90% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 30.45 | +0.73% | 1,424,648 |
24-03-26 | 30.23 | -0.17% | 1,541,953 |
24-03-25 | 30.28 | +0.03% | 1,321,137 |
24-03-22 | 30.27 | -0.53% | 1,591,081 |
24-03-21 | 30.43 | +0.07% | 2,172,869 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.40% | 13.6B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.55% | 210B | |
+1.08% | 210B | |
-6.81% | 201B | |
-3.51% | 157B |